ROBBIN* Phase 3: Neoadjuvant BOT+BAL in High-Risk Stage II and Stage III MSS Colon Cancer

Trial Size
- N=850

Patient Population
- High Risk Stage II (cT4aN0M0) and Stage III (cT3-T4Na+M0) resectable MSS colon cancer
- ECOG 0 or 1
- Age ≥18 years


Target Endpoints

Primary: Event-free survival (EFS)

Key Secondary:
- Overall survival
- Circulating tumor DNA (ctDNA) negativity

Additional Secondary:
- HR-QoL
- Safety
- Sparse pharmacokinetic analyses

Exploratory Endpoints
- Pathologic response rate
- Pathologic response correlation with EFS and OS
- Utilization of adjuvant chemo
- Biomarkers



†Adjuvant chemotherapy or observation in both arms to be decided by investigator per standard of care based on pathologic stage and society guidelines.

1 *A Phase 3 **R**andomized, **O**pen-Label Study of **B**otensilimab Plus **B**alstilimab **I**n the **N**eoadjuvant Setting followed by Standard of Care Versus Standard of Care Alone in Previously Untreated High-Risk Stage II and Stage III Non–MSI-H/dMMR Colon Cancer (**ROBBIN** Study)

agenus